CDIO (Cardio Diagnostics Holdings) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDIO Cardio Diagnostics Holdings Inc CDIO
49 GF Score
Price $1.57
GF Value $2.77
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cardio Diagnostics Holdings Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Cardio Diagnostics Holdings's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

CDIO vs ERNA, LABT, JAGX: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardio Diagnostics Holdings Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Margin of Safety % (DCF Dividends Based) falls into.


CDIO
49GF Score
Cardio Diagnostics Holdings Inc CDIO
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?

Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued. The current stock price of $1.57 is trading 43.3% below its estimated GF Value™ of $2.77. GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.

Key valuation signals for CDIO:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $2.77 vs. price of $1.57 (43.3% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardio Diagnostics Holdings Business Description

Address 311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score

Get the complete analysis for CDIO

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.57
Price
$2.77
GF Value